Evidence map›Paper›PMID 28935884›Full record

ArticleScientific reports2017

Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins.

Clovis Chabert, Saadi Khochbin, Sophie Rousseaux, Rebecca Furze, Nicholas Smithers, Rab Prinjha, Uwe Schlattner, Christophe Pison, Hervé Dubouchaud

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Clovis ChabertUniv. Grenoble Alpes, Inserm, Laboratoire de Bioénergétique Fondamentale et Appliquée (LBFA), Grenoble, 38000, France.
Saadi KhochbinUniv. Grenoble Alpes, Inserm, CNRS, Institute for Advanced Biosciences (IAB), Grenoble, 38000, France.
Sophie RousseauxUniv. Grenoble Alpes, Inserm, CNRS, Institute for Advanced Biosciences (IAB), Grenoble, 38000, France.
Rebecca FurzeEpigenetics DPU, Immuno-Inflammation Therapy Area, Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, SG1 2NY, England, UK.
Nicholas SmithersEpigenetics DPU, Immuno-Inflammation Therapy Area, Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, SG1 2NY, England, UK.
Rab PrinjhaEpigenetics DPU, Immuno-Inflammation Therapy Area, Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, SG1 2NY, England, UK.ORCID 0000-0002-2666-3326
Uwe SchlattnerUniv. Grenoble Alpes, Inserm, Laboratoire de Bioénergétique Fondamentale et Appliquée (LBFA), Grenoble, 38000, France.
Christophe PisonUniv. Grenoble Alpes, Inserm, Laboratoire de Bioénergétique Fondamentale et Appliquée (LBFA), Grenoble, 38000, France.
Hervé DubouchaudUniv. Grenoble Alpes, Inserm, Laboratoire de Bioénergétique Fondamentale et Appliquée (LBFA), Grenoble, 38000, France. herve.dubouchaud@univ-grenoble-alpes.fr.ORCID 0000-0003-1268-6110
Inserm · FRGlaxoSmithKline (United Kingdom) · GBCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some of the Chronic Obstructive Pulmonary Disease (COPD) patients engaged in exercise-based muscle rehabilitation programs are unresponsive. To unravel the respective role of chronic hypoxia and pulmonary inflammation on soleus muscle hypertrophic capacities, we challenged male Wistar rats to repeated lipopolysaccharide instillations, associated or not with a chronic hypoxia exposure. Muscle hypertrophy was initiated by bilateral ablation of soleus agonists 1 week before sacrifice. To understand the role played by the histone acetylation, we also treated our animals with an inhibitor of bromodomains and extra terminal proteins (I-BET) during the week after surgery. Pulmonary inflammation totally inhibited this hypertrophy response under both normoxic and hypoxic conditions (26% lower than control surgery, p < 0.05), consistent with the S6K1 and myogenin measurements. Changes in histone acetylation and class IIa histone deacetylases expression, following pulmonary inflammation, suggested a putative role for histone acetylation signaling in the altered hypertrophy response. The I-BET drug restored the hypertrophy response suggesting that the non-response of muscle to a hypertrophic stimulus could be modulated by epigenetic mechanisms, including histone-acetylation dependant pathways. Drugs targeting such epigenetic mechanisms may open therapeutic perspectives for COPD patients with systemic inflammation who are unresponsive to rehabilitation.

Indexed as

AcetylationAnimalsHeterocyclic Compounds, 4 or More RingsHistonesHumansHypertrophyHypoxiaMaleMuscle, SkeletalMuscular DiseasesPneumoniaProtein DomainsPulmonary Disease, Chronic ObstructiveRats, WistarGSK1210151AHeterocyclic Compounds, 4 or More RingsHistones

Identifiers

PMID28935884
PMCPMC5608715
OpenAlexW2755760408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.